To discuss advancements in glioblastoma research and treatment strategies, particularly addressing the historical challenges in treatment.
Approach:
Key Findings:
Tumor-treating fields are the only addition to standard care showing survival benefits.
Monotherapies targeting single pathways are unlikely to succeed due to GBM's complex biology and historical treatment failures.
CSF detection rates for glioma are significantly higher than plasma, with molecular concordance with tissue samples.
Interpretation:
The editorial reflects on the historical challenges in glioblastoma treatment, emphasizing the need for innovative, multi-faceted approaches to overcome these obstacles.
Limitations:
Current non-invasive detection methods are not ready for routine clinical practice, limiting early diagnosis.
The complexity of GBM biology complicates the development of effective therapies, necessitating more research.
Conclusion:
The editorial calls for a shift in focus towards combination strategies and better diagnostic tools to improve glioblastoma management, stressing the urgency of addressing these challenges.
